Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) Revenue (2019 - 2023)

Benitec Biopharma's Revenue history spans 5 years, with the latest figure at $7000.0 for Q2 2023.

  • For Q2 2023, Revenue changed N/A year-over-year to $7000.0; the TTM value through Mar 2024 reached $7000.0, down 89.71%, while the annual FY2023 figure was $75000.0, 2.74% up from the prior year.
  • Revenue for Q2 2023 was $7000.0 at Benitec Biopharma, down from $54000.0 in the prior quarter.
  • Across five years, Revenue topped out at $77000.0 in Q4 2019 and bottomed at -$41000.0 in Q2 2020.
  • The 5-year median for Revenue is $25000.0 (2021), against an average of $23384.6.
  • The largest annual shift saw Revenue tumbled 98.7% in 2020 before it skyrocketed 4700.0% in 2022.
  • A 5-year view of Revenue shows it stood at $77000.0 in 2019, then crashed by 98.7% to $1000.0 in 2020, then soared by 2400.0% to $25000.0 in 2021, then tumbled by 44.0% to $14000.0 in 2022, then crashed by 50.0% to $7000.0 in 2023.
  • Per Business Quant, the three most recent readings for BNTC's Revenue are $7000.0 (Q2 2023), $54000.0 (Q1 2023), and $14000.0 (Q4 2022).